Full year Net Loss of $206.4M and Adjusted Net Income of $206.7M Continued value driver execution drove full year Adjusted EBITDA of $331.7M Full year Loss Per Diluted Share of $1.37 and Adjusted ...
While FDA reviews PMA application for the upcoming Perimeter B-Series (Company continues to anticipate Agency's decision in H1-2026) , commercial market traction with the current S-Series has grown Q3 ...
"We are very much looking forward to sharing the primary endpoint results of the pivotal clinical trial evaluating our proprietary B-Series OCT with ImgAssist AI in breast-conserving surgeries," ...
The Company continues to gain significant positive commercial market traction with its first U.S. Food and Drug Administration ("FDA")-cleared product, Perimeter S-Series: "As energized as we are by ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results